致力于研发和商业化创新肿瘤疗法的领先生物制药公司--德琪医药有限公司(简称“德琪医药”，香港联交所股票代码：6996.HK)今日宣布，同类首款选择性核输出抑制剂——塞利尼索(selinexor)12项研究及成果入选欧洲血液学协会(EHA)年会。此届 EHA 会议将于6月9日至6月17日在线上召开。

　　线上摘要

　　Phase 2 MARCH study of oral ATG-010 plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously exposed to an immunomodulatory agent and a proteasome inhibitor.

　　摘要编号：PB1670

　　Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.

　　摘要编号：S188

　　Selinexor containing regimens in patients with multiple myeloma previously treated with anti-CD38 monoclonal antibodies.

　　摘要编号：EP1002

　　Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed/refractory multiple myeloma (MM).

　　摘要编号：EP1008

　　Ciltacabtagene Autoleucel versus selinexor + dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) treated with ≥ 3 lines of prior therapy：A matching adjusted indirect comparison.

　　摘要编号：EP1049

　　Cost effectiveness comparison of belantamab mafodotin and selinexor in relapsed refractory multiple myeloma.

　　摘要编号：EP1173

　　Lymphocyte count effect on efficacy and safety of single agent oral selinexor in patients with relapsed/refractory diffuse large B-cell lymphoma(DLBCL)：A post-hoc analysis from phase 2B SADAL study.

　　摘要编号：EP530

　　Genomic correlates of respones to selinexor in multiple myeloma from the BOSTON study reveal a predictive signature.

　　摘要编号：EP936

　　Effects of selinexor on previously treated multiple myeloma (MM) with RAS-mutations.

　　摘要编号：EP966

　　Efficacy and safety of selinexor, bortezomib, and dexamethasone based on refractory status to lenalidomide in patients with previously treated multiple myeloma：A post-hoc analysis of the BOSTON study.

　　摘要编号：EP974

　　Survival among older patients with previously treated multiple myeloma treated with selinexor，bortezomib, and dexamethasone (XVd) in the BOSTON study.

　　摘要编号：EP976

　　Updated overall survival of eltanexor for the treatment of patients with hypomethylating agent refractory myelodysplastic syndrome.

　　摘要编号：EP924

　　关于德琪医药

　　德琪医药有限公司(简称“德琪医药”，香港联交所股票代码：6996.HK)是一家以研发为驱动的生物制药领先企业，致力于为亚太乃至全球患者提供最领先的疗法，治疗肿瘤及其他危及生命的疾病。自2017年正式运营以来，德琪医药通过合作引进和自主研发，建立了一条从临床前到临床阶段不断延展的丰富产品管线。目前，德琪医药已在多个亚太市场获得15个临床批件(IND)，并递交了5个新药上市申请(NDA)。德琪医药将以“医者无疆，创新永续”为愿景，专注于同类首款和同类最优疗法的早期研发、临床研究、药物生产及商业化，解决亟待满足的临床需求。